Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 251

1.

Resting functional connectivity in social anxiety disorder and the effect of pharmacotherapy.

Doruyter A, Lochner C, Jordaan GP, Stein DJ, Dupont P, Warwick JM.

Psychiatry Res. 2016 May 30;251:34-44. doi: 10.1016/j.pscychresns.2016.04.009. Epub 2016 Apr 16.

PMID:
27111811
2.

SECOND-STAGE TREATMENTS FOR RELATIVE NONRESPONDERS TO COGNITIVE BEHAVIORAL THERAPY (CBT) FOR PANIC DISORDER WITH OR WITHOUT AGORAPHOBIA-CONTINUED CBT VERSUS SSRI: A RANDOMIZED CONTROLLED TRIAL.

Payne LA, White KS, Gallagher MW, Woods SW, Shear MK, Gorman JM, Farchione TJ, Barlow DH.

Depress Anxiety. 2016 May;33(5):392-9. doi: 10.1002/da.22457. Epub 2015 Dec 10.

PMID:
26663632
3.

Selective serotonin reuptake inhibitors for fibromyalgia syndrome.

Riera R.

Sao Paulo Med J. 2015 Sep-Oct;133(5):454. doi: 10.1590/1516-3180.20151335T1.

5.

Cognitive and psychomotor effects of three months of escitalopram treatment in elderly patients with major depressive disorder.

Beheydt LL, Schrijvers D, Docx L, Bouckaert F, Hulstijn W, Sabbe B.

J Affect Disord. 2015 Dec 1;188:47-52. doi: 10.1016/j.jad.2015.08.041. Epub 2015 Aug 28.

PMID:
26342888
6.

Antidepressants and their effect on cognition in major depressive disorder.

Papakostas GI.

J Clin Psychiatry. 2015 Aug;76(8):e1046. doi: 10.4088/JCP.13086tx5c. Review.

7.

Interventions for Neuropsychiatric Symptoms in Neurocognitive Impairment Due to Alzheimer's Disease: A Review of the Literature.

McClam TD, Marano CM, Rosenberg PB, Lyketsos CG.

Harv Rev Psychiatry. 2015 Sep-Oct;23(5):377-93. doi: 10.1097/HRP.0000000000000097. Review.

PMID:
26332220
8.

Trial design innovations: Clinical trials for treatment of neuropsychiatric symptoms in Alzheimer's Disease.

Cummings J, Zhong K.

Clin Pharmacol Ther. 2015 Nov;98(5):483-5. doi: 10.1002/cpt.190. Epub 2015 Aug 31. Review.

PMID:
26206713
9.

Cognitive control, reward-related decision making and outcomes of late-life depression treated with an antidepressant.

Alexopoulos GS, Manning K, Kanellopoulos D, McGovern A, Seirup JK, Banerjee S, Gunning F.

Psychol Med. 2015 Oct;45(14):3111-20. doi: 10.1017/S0033291715001075. Epub 2015 Jul 14.

10.

Advancements in the treatment of agitation in Alzheimer's disease.

Antonsdottir IM, Smith J, Keltz M, Porsteinsson AP.

Expert Opin Pharmacother. 2015;16(11):1649-56. doi: 10.1517/14656566.2015.1059422. Review.

PMID:
26159445
11.

Treatment with escitalopram improves the attentional bias toward negative facial expressions in patients with major depressive disorders.

Zhou Z, Cao S, Li H, Li Y.

J Clin Neurosci. 2015 Oct;22(10):1609-13. doi: 10.1016/j.jocn.2015.03.036. Epub 2015 Jul 3.

PMID:
26149404
12.

Influence of anxiety symptoms on improvement of neurocognitive functions in patients with major depressive disorder: A 12-week, multicenter, randomized trial of tianeptine versus escitalopram, the CAMPION study.

Yoo I, Woo JM, Lee SH, Fava M, Mischoulon D, Papakostas GI, Kim EJ, Chung S, Ha JH, Jeon HJ.

J Affect Disord. 2015 Oct 1;185:24-30. doi: 10.1016/j.jad.2015.06.038. Epub 2015 Jun 25.

PMID:
26142691
13.

Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis.

Stinton C, McKeith I, Taylor JP, Lafortune L, Mioshi E, Mak E, Cambridge V, Mason J, Thomas A, O'Brien JT.

Am J Psychiatry. 2015 Aug 1;172(8):731-42. doi: 10.1176/appi.ajp.2015.14121582. Epub 2015 Jun 18. Review.

PMID:
26085043
14.

Selective serotonin reuptake inhibitors for fibromyalgia syndrome.

Walitt B, Urrútia G, Nishishinya MB, Cantrell SE, Häuser W.

Cochrane Database Syst Rev. 2015 Jun 5;(6):CD011735. doi: 10.1002/14651858.CD011735. Review.

15.

Cognitive Behavioral Analysis System of Psychotherapy versus Escitalopram in Chronic Major Depression.

Schramm E, Zobel I, Schoepf D, Fangmeier T, Schnell K, Walter H, Drost S, Schmidt P, Brakemeier EL, Berger M, Normann C.

Psychother Psychosom. 2015;84(4):227-40. doi: 10.1159/000381957. Epub 2015 May 23.

PMID:
26022410
16.

Similar changes in cognitions following cognitive-behavioral therapy or escitalopram for major depressive disorder: Implications for mechanisms of change.

Farabaugh A, Fisher L, Nyer M, Holt D, Cohen M, Baer L, Shapero BG, Huz I, Cardoos A, Fava M, Alpert JE.

Ann Clin Psychiatry. 2015 May;27(2):118-26.

PMID:
25954938
17.

Effects of lisdexamfetamine alone and in combination with s-citalopram on acetylcholine and histamine efflux in the rat pre-frontal cortex and ventral hippocampus.

Hutson PH, Heins MS, Folgering JH.

J Neurochem. 2015 Aug;134(4):693-703. doi: 10.1111/jnc.13157. Epub 2015 Jun 3.

PMID:
25946513
18.

Efficacy of treatments for anxiety disorders: a meta-analysis.

Bandelow B, Reitt M, Röver C, Michaelis S, Görlich Y, Wedekind D.

Int Clin Psychopharmacol. 2015 Jul;30(4):183-92. doi: 10.1097/YIC.0000000000000078. Review.

PMID:
25932596
19.

ABCB1 Genetic Effects on Antidepressant Outcomes: A Report From the iSPOT-D Trial.

Schatzberg AF, DeBattista C, Lazzeroni LC, Etkin A, Murphy GM Jr, Williams LM.

Am J Psychiatry. 2015 Aug 1;172(8):751-9. doi: 10.1176/appi.ajp.2015.14050680. Epub 2015 Mar 27.

PMID:
25815420
20.

[Therapy of dementia with antipsychotics and antidepressives].

Frölich L, Hausner L.

Nervenarzt. 2015 Apr;86(4):461-7. doi: 10.1007/s00115-014-4178-4. Review. German.

PMID:
25787724
Items per page

Supplemental Content

Loading ...
Write to the Help Desk